{"id":1062,"date":"2001-07-01T12:03:00","date_gmt":"2001-07-01T10:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/pentasaccharide-eine-neue-antikoagulanzien-familie"},"modified":"2022-03-17T14:09:52","modified_gmt":"2022-03-17T13:09:52","slug":"pentasaccharide-eine-neue-antikoagulanzien-familie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/pentasaccharide-eine-neue-antikoagulanzien-familie","title":{"rendered":"Pentasaccharide, eine neue Antikoagulanzien-Familie"},"content":{"rendered":"<p>Synthetische Pentasaccharide sind neue Antikoagulanzien aus dem Drug-Designer-Labor. Sie \u00e4hneln in ihrer molekularen Struktur der Region aus dem Heparin-Molek\u00fcl, die f\u00fcr die Bindung an Antithrombin III (AT III) verantwortlich ist. Wie die Heparine wirken auch diese Pentasaccharide als Wirkverst\u00e4rker von AT III. Sie verursachen eine \u00c4nderung der Konformation von AT III und potenzieren seine Anti-Faktor-X-Wirkung. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Synthetische Pentasaccharide sind neue Antikoagulanzien aus dem Drug-Designer-Labor. Sie \u00e4hneln in ihrer molekularen Struktur der Region aus dem Heparin-Molek\u00fcl, die f\u00fcr die Bindung an Antithrombin III (AT III) verantwortlich ist. Wie die Heparine wirken auch diese Pentasaccharide als Wirkverst\u00e4rker von AT III. Sie verursachen eine \u00c4nderung der Konformation von AT III und potenzieren seine Anti-Faktor-X-Wirkung. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[137,2658,2659],"class_list":["post-1062","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antikoagulanzien","tag-org31540-sr90107a","tag-pentasaccharide"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1062"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1062\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}